LifeSci Acquisition Corporation, a Special Purpose Acquisition Company, Sponsored by an Affiliate of LifeSci Partners, Announces the Acquisition of Vincera Pharma
LifeSci Acquisition Corp. (Nasdaq: LSAC, LSACU AND LSACW) is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities, pursuing targets that are focused on healthcare innovation in North America or Europe.
Chief Executive Officer
Chief Operating Officer
Chief Financial Officer
Board of Directors
• Barry Dennis
• John Ziegler, M.D.
• Jonas Grossman
• Karin Walker
Vincera is a recently formed clinical-stage biopharmaceutical company leveraging its extensive development and oncology expertise to advance new therapies to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics. Vincera’s management team of biopharmaceutical experts has an industry-leading track record of discovering and developing blockbuster oncology drugs.
Vincera’s current pipeline is derived from an exclusive option to license agreement with Bayer for an oncology portfolio which includes (i) a clinical-stage small molecule PTEFb/CDK9 inhibitor with a follow-on oral program and (ii) a preclinical next-generation bioconjugation platform to overcome the limitations of antibody and small molecule drug conjugates. The company intends to leverage strong partnerships to develop multiple products with the potential for accelerated approvals through clinical proof-of-concept.
To learn more about Vincera, please visit https://vincerapharma.com/